Atopic Dermatitis

An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.

Christopher Bunick, MD, PhD, examines patient satisfaction upon achieving primary study endpoints in clinical trials and highlights the significance of patient-reported outcomes (PROs) in both clinical trial designs and patient care.

Shawn Kwatra, MD, discusses the durability of treatments for atopic dermatitis and provides advice for clinicians on improving patients’ quality of life.

An expert on skin conditions provides an overview of TARGET-DERM, a real-world study of patient-reported outcomes in atopic dermatitis.

Shawn Kwatra, MD, provides an overview of oral JAK inhibitors for the treatment of atopic dermatitis, highlighting data from clinical trials.

An expert in the treatment of atopic dermatitis shares her perspectives on patient communication and treatment optimization practices.

An academic dermatologist discusses the safety profiles of abrocitinib and upadacitinib and provides clinical insights on patient monitoring practices.

Ruth Ann Vleugels, MD, MPH, MBA, provides insights on factors that inform JAK inhibitor treatment selection for patients with atopic dermatitis.

An expert on atopic dermatitis identifies patients who are good candidates for JAK inhibitors, highlighting contraindications for treatment.

A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.

An atopic dermatitis expert discusses the primary and secondary efficacy endpoints and treatment goals commonly assessed in clinical trials for moderate to severe atopic dermatitis.

Christopher Bunick, MD, PhD, advises on when to consider systemic treatments and the frequency of moving to advanced treatments for patients with moderate to severe atopic dermatitis.

An expert on atopic dermatitis provides insights on how the evolving treatment landscape has impacted clinician and patient expectations.

Shawn Kwatra, MD, discusses the effects of poorly controlled or severe atopic dermatitis on patients’ quality of life and how to measure patient-reported outcomes.

An academic dermatologist describes how JAK inhibitors compare with other systemic treatments for atopic dermatitis and provides clinical insights on when to use which treatments.

Ruth Ann Vleugels, MD, MPH, MBA, provides an overview of oral JAK inhibitors approved for the treatment of atopic dermatitis and describes what makes them an attractive therapeutic option.

In this interview, Chovatiya discussed the recent FDA approval of roflumilast cream 0.15% for patients with eczema aged 6 years and older.

This decision by FDA officials resulted from the INTEGUMENT study findings which determined that once-daily roflumilast led to rapid eczema clearance and significant disease reductions.

These findings also highlighted the necessity of identifying the clinically relevant comorbidities of asthma and allergic rhinitis in a proactive manner.

Arcutis Biotherapeutics announced the update and indicated the FDA was working to finalize the action letter on July 09, 2024, which was 2 days after the assigned PDUFA date of July 07, 2024.

These updated guidelines by the AAAAI and ACAAI Joint Task Force incorporate additional research regarding treatment options for eczema.

These findings confirm the ways in which patient responses in the head and neck areas contribute to modifications in life quality among those with eczema.

This retrospective study highlighted the results of Singaporean atopic dermatitis patients aged 18 years and below who had undergone phototherapy.

Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.

This analysis from Spain assessed the short-term effectiveness and safety of abrocitinib within a real-world setting for those with moderate-to-severe eczema.